Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced the U.S. Food and Drug Administration (FDA) approved Rituxan (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

EntreMed, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

New research, 'Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double- blind study of estradiol and risedronate: N01C8,' is the subject of a report. The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer.

Prostate cancer cells are more likely to spread to other parts of the body if a specific gene quits functioning normally, according to new data from researchers at UT Southwestern Medical Center.

Calypso Medical Technologies, Inc., a developer of targeting technology used for accurate, precise real-time tracking of tumor targets, announced the online publication of a clinical study in Urology (The GOLD JOURNAL).

Investigators publish new data in the report 'Levels of sex hormones have limited effect on cognition in older men with or without prostate cancer.' According to recent research published in the journal Critical Reviews In Oncology, Androgen deprivation therapy is commonly used to treat prostate cancer, but by lowering testosterone levels it may affect cognitive function. However, the relationship between testosterone and cognition remains unclear.

Breast cancer patients are increasingly having preventive surgery to remove the unaffected breast, but a new study suggests it's not beneficial for the vast majority of women who undergo it.

Researchers detail in 'Male breast cancer,' new data in breast cancer. According to recent research published in the journal Critical Reviews In Oncology, Male breast cancer (MaleBC) is a rare disease, accounting for <1% of all male tumors. During the last few years, there has been an increase in the incidence of this disease, along with the increase in female breast cancer (FBC).

A University of Melbourne study has revealed that certain breast cancer genetic variants increase mammographic density, confirming the link between mammographic breast density and breast cancer. Professor John Hopper of the University's School of Population Health says women vary greatly in their underlying risk of breast cancer. These findings provide an insight into possible new pathways into the development of breast cancer.